X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/09/28/2751457/0/en/AI-Therapeutics-Announces-Name-Change-to-OrphAI-Therapeutics.html
https://www.globenewswire.com//news-release/2023/08/31/2735462/0/en/AI-Therapeutics-Announces-Initiation-of-a-Phase-2-Clinical-Trial-of-LAM-001-for-Treatment-of-Pulmonary-Arterial-Hypertension-PAH.html
https://www.globenewswire.com//news-release/2023/08/18/2728101/0/en/AI-Therapeutics-Announces-Investigator-Initiated-Phase-2-Trial-at-UCSF-to-Study-LAM-001-in-Patients-With-Bronchiolitis-Obliterans-Syndrome-BOS-Post-Lung-Transplant.html
https://www.globenewswire.com/news-release/2023/07/12/2703751/0/en/AI-Therapeutics-Announces-Appointment-of-Biotechnology-Industry-Leader-David-Scheer-as-Chairman-of-the-Board-of-Directors.html
https://www.globenewswire.com/news-release/2023/05/09/2664682/0/en/AI-Therapeutics-Announces-Poster-Presentation-at-the-2023-American-Thoracic-Society-International-Conference.html
https://www.fiercebiotech.com/biotech/yale-aligned-biotech-ai-therapeutics-says-als-med-was-safe-and-promising-phase-2-trial
https://www.globenewswire.com/news-release/2023/04/05/2641635/0/en/AI-Therapeutics-Announces-Positive-Results-from-Phase-2a-Biomarker-driven-Trial-of-AIT-101-in-Patients-with-C9ORF72-Amyotrophic-Lateral-Sclerosis-ALS.html
https://www.globenewswire.com/news-release/2022/04/25/2428314/0/en/AI-Therapeutics-Announces-the-Acquisition-of-Novel-Cancer-Drug-Candidate-EC-8042-AIT-102.html
https://www.globenewswire.com/news-release/2022/02/16/2386426/0/en/AI-Therapeutics-Appoints-Brigette-Roberts-M-D-as-Chief-Executive-Officer.html
https://www.globenewswire.com/news-release/2022/01/13/2366651/0/en/AI-Therapeutics-Announces-Initiation-of-a-Phase-II-Clinical-Trial-of-AIT-101-for-Treatment-of-ALS.html
Market Place
Share 
